Sangamo Therapeutics Past Earnings Performance
Past criteria checks 0/6
Sangamo Therapeutics's earnings have been declining at an average annual rate of -21.1%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 17.4% per year.
Key information
-21.1%
Earnings growth rate
-10.4%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 17.4% |
Return on equity | -311.1% |
Net Margin | -146.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Sangamo Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 176 | -258 | 57 | 0 |
30 Sep 23 | 201 | -250 | 63 | 0 |
30 Jun 23 | 218 | -199 | 67 | 0 |
31 Mar 23 | 241 | -127 | 66 | 0 |
31 Dec 22 | 111 | -192 | 63 | 0 |
30 Sep 22 | 112 | -178 | 62 | 0 |
30 Jun 22 | 114 | -172 | 61 | 0 |
31 Mar 22 | 113 | -176 | 62 | 0 |
31 Dec 21 | 111 | -178 | 63 | 0 |
30 Sep 21 | 109 | -181 | 64 | 0 |
30 Jun 21 | 138 | -135 | 66 | 0 |
31 Mar 21 | 131 | -124 | 67 | 0 |
31 Dec 20 | 118 | -121 | 67 | 0 |
30 Sep 20 | 147 | -76 | 65 | 0 |
30 Jun 20 | 111 | -102 | 64 | 0 |
31 Mar 20 | 107 | -96 | 61 | 0 |
31 Dec 19 | 102 | -95 | 62 | 0 |
30 Sep 19 | 74 | -118 | 61 | 0 |
30 Jun 19 | 76 | -104 | 57 | 0 |
31 Mar 19 | 80 | -90 | 54 | 0 |
31 Dec 18 | 84 | -68 | 47 | 0 |
30 Sep 18 | 71 | -63 | 40 | 0 |
30 Jun 18 | 59 | -62 | 35 | 0 |
31 Mar 18 | 46 | -58 | 30 | 0 |
31 Dec 17 | 37 | -55 | 27 | 0 |
30 Sep 17 | 32 | -51 | 23 | 0 |
30 Jun 17 | 23 | -58 | 23 | 0 |
31 Mar 17 | 19 | -72 | 22 | 0 |
31 Dec 16 | 19 | -72 | 22 | 0 |
30 Sep 16 | 20 | -76 | 22 | 0 |
30 Jun 16 | 25 | -66 | 20 | 0 |
31 Mar 16 | 30 | -52 | 20 | 0 |
31 Dec 15 | 40 | -41 | 19 | 0 |
30 Sep 15 | 45 | -31 | 19 | 0 |
30 Jun 15 | 49 | -29 | 18 | 0 |
31 Mar 15 | 51 | -24 | 17 | 0 |
31 Dec 14 | 46 | -26 | 16 | 0 |
30 Sep 14 | 38 | -30 | 16 | 0 |
30 Jun 14 | 31 | -29 | 15 | 0 |
31 Mar 14 | 28 | -27 | 14 | 0 |
31 Dec 13 | 24 | -27 | 14 | 0 |
30 Sep 13 | 26 | -22 | 13 | 0 |
30 Jun 13 | 25 | -22 | 13 | 0 |
Quality Earnings: GBY is currently unprofitable.
Growing Profit Margin: GBY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GBY is unprofitable, and losses have increased over the past 5 years at a rate of 21.1% per year.
Accelerating Growth: Unable to compare GBY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GBY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: GBY has a negative Return on Equity (-311.06%), as it is currently unprofitable.